Syndecan-1 (SDC1, CD138) is a cell surface proteoglycan that plays a pivotal role in cancer progression, metastasis, immune evasion, and drug resistance. Aberrant glycosylation of Syndecan-1, particularly the Tn-glycoform, represents a distinct cancer-specific alteration that is rarely found in healthy tissues. Targeting this abnormal Tn-glycoform of Syndecan-1 provides a highly selective therapeutic approach, enhancing specificity and minimizing off-target effects. Combotope’s innovative antibody platform is uniquely designed to exploit this differential glycosylation, offering new possibilities for precision oncology.

Figure: ELISA experiment demonstrating specific binding of Combotope anti-Tn-Syndecan IgG mAb